AGILON HEALTH INC (AGL)
US00857U1079 - Common Stock
AGL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 113 industry peers in the Health Care Providers & Services industry. AGL may be in some trouble as it scores bad on both profitability and health. AGL shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year AGL has reported negative net income.
AGL had a negative operating cash flow in the past year.
AGL had negative earnings in each of the past 5 years.
AGL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
AGL has a worse Return On Assets (-18.40%) than 76.99% of its industry peers.
AGL's Return On Equity of -66.94% is on the low side compared to the rest of the industry. AGL is outperformed by 73.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.4% | ||
| ROE | -66.94% | ||
| ROIC | N/A |
ROA(3y)-15.66%
ROA(5y)-26.12%
ROE(3y)-29.05%
ROE(5y)-181.24%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 2.00%, AGL is not doing good in the industry: 84.07% of the companies in the same industry are doing better.
AGL's Gross Margin has declined in the last couple of years.
AGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 2% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.83%
GM growth 5YN/A
2. Health
2.1 Basic Checks
AGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
AGL has less shares outstanding than it did 1 year ago.
AGL has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.53, we must say that AGL is in the distress zone and has some risk of bankruptcy.
AGL has a Altman-Z score of 1.53. This is comparable to the rest of the industry: AGL outperforms 45.13% of its industry peers.
AGL has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
AGL's Debt to Equity ratio of 0.06 is fine compared to the rest of the industry. AGL outperforms 76.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.53 |
ROIC/WACCN/A
WACC9.16%
2.3 Liquidity
AGL has a Current Ratio of 1.29. This is a normal value and indicates that AGL is financially healthy and should not expect problems in meeting its short term obligations.
AGL has a Current ratio of 1.29. This is in the lower half of the industry: AGL underperforms 61.06% of its industry peers.
AGL has a Quick Ratio of 1.29. This is a normal value and indicates that AGL is financially healthy and should not expect problems in meeting its short term obligations.
AGL has a Quick ratio (1.29) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 |
3. Growth
3.1 Past
The earnings per share for AGL have decreased strongly by -254.55% in the last year.
The Revenue has grown by 27.75% in the past year. This is a very strong growth!
AGL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 52.45% yearly.
EPS 1Y (TTM)-254.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-262.5%
Revenue 1Y (TTM)27.75%
Revenue growth 3Y52.45%
Revenue growth 5YN/A
Sales Q2Q%19.35%
3.2 Future
AGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 48.20% yearly.
Based on estimates for the next years, AGL will show a very strong growth in Revenue. The Revenue will grow by 21.92% on average per year.
EPS Next Y20.08%
EPS Next 2Y22.76%
EPS Next 3Y25.08%
EPS Next 5Y48.2%
Revenue Next Year34.3%
Revenue Next 2Y28.14%
Revenue Next 3Y25.94%
Revenue Next 5Y21.92%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
AGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AGL's earnings are expected to grow with 25.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.76%
EPS Next 3Y25.08%
5. Dividend
5.1 Amount
No dividends for AGL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AGILON HEALTH INC
NYSE:AGL (11/21/2024, 7:06:06 PM)
After market: 1.77 -0.01 (-0.56%)1.78
+0.11 (+6.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap733.40M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.4% | ||
| ROE | -66.94% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 2% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover2.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-254.55%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y20.08%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)27.75%
Revenue growth 3Y52.45%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y